EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Survival by time‐to‐administration of amiodarone, lidocaine, or placebo in shock‐refractory out‐of‐hospital cardiac arrest

Joshua R Lupton iD, Matthew R Neth, Ritu Sahni, Jonathan Jui, Lynn Wittwer, Craig D Newgard iD, Mohamud R Daya

Academic Emergency Medicine · 2023

DOI: 10.1111/acem.14716 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Academic Emergency Medicine, 2023. Verfasst von Joshua R Lupton und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Amiodarone, Out-of-Hospital Cardiac Arrest, Emergency Medical Services, Cardiopulmonary Resuscitation. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Society for Academic Emergency Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Amiodarone and lidocaine have not been shown to have a clear survival benefit compared to placebo for out‐of‐hospital cardiac arrest (OHCA). However, randomized trials may have been impacted by delayed administration of the study drugs. We sought to evaluate how timing from emergency medical services (EMS) arrival on scene to drug administration affects the efficacy of amiodarone and lidocaine compared to placebo.

Method

This is a secondary analysis of the 10‐site, 55‐EMS‐agency double‐blind randomized controlled amiodarone, lidocaine, or placebo in OHCA study. We included patients with initial shockable rhythms who received the study drugs of amiodarone, lidocaine, or placebo before achieving return of spontaneous circulation. We performed logistic regression analyses evaluating survival to hospital discharge and secondary outcomes of survival to admission and functional survival (modified Rankin scale score ≤ 3). We evaluated the samples stratified by early ( 0.05).

Conclusions

The early administration of amiodarone, particularly within 8 min, is associated with greater survival to admission, survival to discharge, and functional survival compared to placebo in patients with an initial shockable rhythm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmiodaroneOut-of-Hospital Cardiac ArrestEmergency Medical ServicesCardiopulmonary ResuscitationHumansLidocaineAnti-Arrhythmia AgentsHospitalization

Substanzen

AmiodaroneLidocaineAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Emergency Medicine, Oregon Health & Science University, Portland, Oregon, USA.

ORCID-Profile: Joshua R Lupton, Craig D Newgard

Förderung

  • Society for Academic Emergency Medicine

Zitieren

APA

Lupton, J. R., Neth, M. R., Sahni, R., Jui, J., Wittwer, L., Newgard, C. D., & Daya, M. R. (2023). Survival by time‐to‐administration of amiodarone, lidocaine, or placebo in shock‐refractory out‐of‐hospital cardiac arrest. Academic Emergency Medicine. https://doi.org/10.1111/acem.14716

Vancouver

Lupton JR, Neth MR, Sahni R, Jui J, Wittwer L, Newgard CD, et al. Survival by time‐to‐administration of amiodarone, lidocaine, or placebo in shock‐refractory out‐of‐hospital cardiac arrest. Academic Emergency Medicine. 2023. doi:10.1111/acem.14716

BibTeX
@article{Lupton2023,
  author = {Lupton, Joshua R and Neth, Matthew R and Sahni, Ritu and Jui, Jonathan and Wittwer, Lynn and Newgard, Craig D and Daya, Mohamud R},
  title = {Survival by time‐to‐administration of amiodarone, lidocaine, or placebo in shock‐refractory out‐of‐hospital cardiac arrest},
  journal = {Academic Emergency Medicine},
  year = {2023},
  doi = {10.1111/acem.14716}
}
Kostenlos starten →